ACCESS Newswire

Promore Pharma

19.11.2021 13:31:49 CET | ACCESS Newswire | Press release

Share
Invitation to Conference Call Regarding Promore Pharma’s Interim Report for the Third Quarter 2021

STOCKHOLM, SE / ACCESSWIRE / November 19, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)

Promore Pharma AB (publ) publishes its interim report for the third quarter 2021 on 23 November 2021.

The next day, 24 November, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.

The number of attendees is limited, please register for the conference in advance on the following link:

https://attendee.gotowebinar.com/register/3513796589233231628

The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.

Attachments

Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2021

SOURCE: Promore Pharma



View source version on accesswire.com:
https://www.accesswire.com/673758/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-Third-Quarter-2021

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner17.9.2026 14:50:00 CEST | Press release

TORONTO, ON AND LONDON, UK / ACCESS Newswire / September 17, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ali Palmer as a Partner in the firm's Human Resources Practice. Based in London, Palmer advises boards, chief executive officers and chief people officers on the recruitment of senior human resources leaders, helping organizations build leadership teams that enable growth, transformation and long-term performance. Ali Palmer, Partner in Caldwell's Human Resources Practice. With more than 20 years of executive search and leadership advisory experience, Palmer partners with listed companies, private equity-backed businesses and privately held organizations across a broad range of sectors, with particular expertise in consumer, retail, industrial, financial services, pharmaceutical and technology. She leads executive search assignments across the full human resources function, from chief people officers and chief human resources

Freedom Holding Corp. Backs the FIDE World Championship Match 2026 as General Partner17.9.2026 14:00:00 CEST | Press release

NEW YORK CITY, NY / ACCESS Newswire / September 17, 2026 / Freedom Holding Corp. (NASDAQ:FRHC) is the General Partner of the Salesforce FIDE World Championship Match 2026, the International Chess Federation (FIDE) and Freedom announced today. General Partner is the highest partnership tier of the World Championship. The Match runs from 22 November to 12 December. The Opening Ceremony takes place on 22 November at the Palais des Nations in Geneva. World Champion Gukesh Dommaraju of India defends his title against Javokhir Sindarov of Uzbekistan over 14 classical games. Both players will be twenty at the start of the Match, the youngest title contest since the series began in 1886. Freedom has been a strategic partner of FIDE since 2023. The group is a regular sponsor of the FIDE World Rapid and Blitz Championships and was the title sponsor of the 2024 FIDE World Corporate Chess Championship in New York. Under a 2026 cooperation agreement, Freedom also funds FIDE tournaments, training ce

Bayer to Present How it Rebuilt Global Planning with OMP at Gartner Supply Chain Planning Summit 202617.9.2026 13:52:00 CEST | Press release

ANTWERPEN, BE / ACCESS Newswire / September 17, 2026 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Planning Summit 2026 in London to its joint session with multinational Bayer. Representatives of the Pharmaceutical division and the global IT department will show what it took to rebuild global planning around faster, higher-quality decisions, how Unison Planning™ supports that at scale, and where AI fits in. Rebuilding planning at Bayer's scale Bayer treated its move to Unison Planning™ as more than a system replacement, rebuilding processes, master data, and ways of working across its global manufacturing and affiliate network. During their Gartner session, Mirja Meyer, Principal Product Manager and Program Lead IT at Bayer, and Karsten Hahm, Program Lead OMP Implementation at Bayer Pharmaceuticals, will cover:What adoption actually tookWhat changed in decision speed and qualityWhere AI fits on the roadmap ahead Sign up for

U.S. Polo Assn. Celebrates New Partnership with the Historic Greenwich Polo Club at the 2026 East Coast Open Presented by Audi17.9.2026 13:00:00 CEST | Press release

WEST PALM BEACH, FL / ACCESS Newswire / September 17, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), celebrated the conclusion of the 2026 East Coast Open Presented by Audi, held August 30 through September 13 at the renowned Greenwich Polo Club in Greenwich, Connecticut, a celebrated polo destination just outside New York City. As the only high-goal tournament on the East Coast during the summer season, the historic championship once again brought together elite international competition for the sport of polo. 2026 East Coast Open Presented by Audi Winners, IGEA, celebrating with tournament trophy. Photo Credit: Greenwich Polo Club The 2026 season also marked a significant milestone as U.S. Polo Assn. served as the Official Apparel Brand Sponsor of Greenwich Polo Club for the first time. The new partnership connected one of the world's most recognized sports brands with one of polo's most iconic venues, further strengthening the brand'

GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops16.9.2026 19:30:00 CEST | Press release

Short Takeoff and Landing Aircraft Validates Austere Field Capabilities SAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / General Atomics Aeronautical Systems (GA-ASI) and Hanwha Aerospace have completed the first-ever flight operations from a simulated battlefield by a medium altitude, long endurance uncrewed aircraft. The partners proved that the Mojave Short Takeoff and Landing aircraft, or Mojave STOL, could land at a tank and artillery live-fire range during simulated combat conditions and then take off again to continue the mission. "This demonstration showcased Mojave's ability to perform tactical missions that are representative of real battlefield requirements and challenges," said GA-ASI CEO Linden Blue. "Whether the user needs contested and austere battlefield operations, ISR, weapons delivery, Air-Launched Effects deployment, troop resupply, counter-UAS, or missions requiring short and unimproved roads for takeoff, our aircraft answer the bell." "This demonstration mar

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye